Although we cannot completely exclude the possibility that a statistically significant increase in relative risk was missed due to the few events in RCTs included and borderline significance of results of secondary leukemia, the rarity of events suggests that such a finding would be very unlikely to change current benefit-risk balance of cisplatin-based chemotherapy in clinical practice.
← all excerpts
Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies.
1
—
—